

2 June 2020

**Proteome Sciences plc  
("Proteome Sciences" or the "Company")**

**Notice of Annual General Meeting**

Proteome Sciences Plc (AIM: PRM), the specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, announces that the Company's 2020 Annual General Meeting (the "AGM") will be held at 11.00 am on 26 June 2020 at Nicholson House, Thames Street, Weybridge KT13 8JG. Notification of the AGM and proxy form have been posted to shareholders and will shortly be available on the Company's website at [www.proteomics.com](http://www.proteomics.com).

In light of the current restrictions on gatherings and non-essential travel related to the COVID-19 pandemic, it is currently envisaged that the AGM will be run as a closed meeting with the minimum necessary quorum of shareholders (being two shareholders) in order to conduct the formal business of the meeting. Whilst the current guidance remains in place, no other shareholders will be permitted to physically attend the meeting. Any shareholder who attempts to attend the meeting will be refused entry.

Shareholders are encouraged to register their votes using the proxy form provided and are strongly encouraged to only appoint the 'Chairman of the meeting' as proxy, as no other proxy will be permitted to attend the meeting. We are providing an opportunity for shareholders to submit written questions relating to the business of the AGM by sending an email to [executive.pa@proteomics.com](mailto:executive.pa@proteomics.com). Questions submitted at least 48 hours prior to the AGM date will be reviewed and responses provided on the Company website at [www.proteomics.com](http://www.proteomics.com).

The Board will keep these AGM arrangements under review and will update shareholders via the Regulatory News Service as appropriate, with any such announcements to be uploaded to the Company's website. The Company encourages shareholders to check its website regularly for the latest information on the arrangements for the AGM.

**For further information please contact:**

**Proteome Sciences plc**

Dr Ian Pike, Interim Chief Executive Officer

Tel: +44 (0)20 7043 2116

Richard Dennis, Chief Commercial Officer

**Allenby Capital Limited (AIM Nominated Adviser & Broker)**

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

**About Proteome Sciences plc. ([www.proteomics.com](http://www.proteomics.com))**

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.